HRP20192273T1 - Specifični trifluoroetil analozi kinolina za upotrebu u liječenju sjögrenovog sindroma - Google Patents
Specifični trifluoroetil analozi kinolina za upotrebu u liječenju sjögrenovog sindroma Download PDFInfo
- Publication number
- HRP20192273T1 HRP20192273T1 HRP20192273TT HRP20192273T HRP20192273T1 HR P20192273 T1 HRP20192273 T1 HR P20192273T1 HR P20192273T T HRP20192273T T HR P20192273TT HR P20192273 T HRP20192273 T HR P20192273T HR P20192273 T1 HRP20192273 T1 HR P20192273T1
- Authority
- HR
- Croatia
- Prior art keywords
- syndrome
- sjögren
- trifluoroethyl
- treatment
- specific
- Prior art date
Links
- 208000021386 Sjogren Syndrome Diseases 0.000 title claims 3
- JOAPFEPXYNWUKS-UHFFFAOYSA-N 2-(2,2,2-trifluoroethyl)quinoline Chemical class C1=CC=CC2=NC(CC(F)(F)F)=CC=C21 JOAPFEPXYNWUKS-UHFFFAOYSA-N 0.000 title 1
- 208000034943 Primary Sjögren syndrome Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 claims 1
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (2)
1. N-{(R)-1-[8-kloro-2-(1-okspirdin-3-il)kinolin-3-il]-2,2,2-trifluoroetil}-pirido[3,2-d]pirimidin-4-ilamin, ili njegova farmaceutska prihvatljiva sol, za upotrebu u liječenju i/ili prevenciji Sjögrenovog sindroma.
2. Spoj za uporabu prema zahtjevu 1, naznačen time da je Sjögrenov sindrom primarni Sjögrenov sindrom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1506786.1A GB201506786D0 (en) | 2015-04-21 | 2015-04-21 | Therapeutic use |
| EP16719356.4A EP3285772B1 (en) | 2015-04-21 | 2016-04-20 | A specific trifluoroethyl quinoline analogue for use in the treatment of sjögren's syndrome |
| PCT/EP2016/058810 WO2016170014A1 (en) | 2015-04-21 | 2016-04-20 | A specific trifluoroethyl quinoline analogue for use in the treatment of sjögren's syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192273T1 true HRP20192273T1 (hr) | 2020-03-06 |
Family
ID=53298950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192273TT HRP20192273T1 (hr) | 2015-04-21 | 2019-12-17 | Specifični trifluoroetil analozi kinolina za upotrebu u liječenju sjögrenovog sindroma |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10493074B2 (hr) |
| EP (1) | EP3285772B1 (hr) |
| JP (1) | JP6721606B2 (hr) |
| KR (1) | KR102627370B1 (hr) |
| CN (1) | CN107530344B (hr) |
| AR (1) | AR105552A1 (hr) |
| AU (1) | AU2016251236B2 (hr) |
| BR (1) | BR112017020591B8 (hr) |
| CA (1) | CA2981631C (hr) |
| CL (1) | CL2017002669A1 (hr) |
| CO (1) | CO2017010573A2 (hr) |
| CY (1) | CY1122572T1 (hr) |
| DK (1) | DK3285772T3 (hr) |
| EA (1) | EA032432B1 (hr) |
| ES (1) | ES2763335T3 (hr) |
| GB (1) | GB201506786D0 (hr) |
| HR (1) | HRP20192273T1 (hr) |
| HU (1) | HUE047162T2 (hr) |
| IL (1) | IL254766B (hr) |
| LT (1) | LT3285772T (hr) |
| MX (1) | MX2017013148A (hr) |
| MY (1) | MY192972A (hr) |
| PL (1) | PL3285772T3 (hr) |
| PT (1) | PT3285772T (hr) |
| SG (1) | SG11201707789YA (hr) |
| SI (1) | SI3285772T1 (hr) |
| WO (1) | WO2016170014A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201708856D0 (en) | 2017-06-02 | 2017-07-19 | Ucb Biopharma Sprl | Seletalisib crystalline forms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2566609C (en) * | 2004-05-13 | 2012-06-26 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| ES2563458T3 (es) * | 2007-03-23 | 2016-03-15 | Amgen Inc. | Compuestos heterocíclicos y sus usos |
| CN105801550B (zh) * | 2009-11-05 | 2019-06-14 | 理森制药股份公司 | 新型苯并吡喃激酶调节剂 |
| UA112517C2 (uk) * | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| AR082799A1 (es) * | 2010-09-08 | 2013-01-09 | Ucb Pharma Sa | Derivados de quinolina y quinoxalina como inhibidores de quinasa |
| SI3008053T1 (en) * | 2013-06-14 | 2018-06-29 | Gilead Calistoga Llc | PHOSPHATIDYLINOSITOL 3-KINATE INHIBITORS |
-
2015
- 2015-04-21 GB GBGB1506786.1A patent/GB201506786D0/en not_active Ceased
-
2016
- 2016-04-20 EA EA201792318A patent/EA032432B1/ru not_active IP Right Cessation
- 2016-04-20 AU AU2016251236A patent/AU2016251236B2/en active Active
- 2016-04-20 SI SI201630565T patent/SI3285772T1/sl unknown
- 2016-04-20 JP JP2017554426A patent/JP6721606B2/ja active Active
- 2016-04-20 AR ARP160101079A patent/AR105552A1/es unknown
- 2016-04-20 PT PT167193564T patent/PT3285772T/pt unknown
- 2016-04-20 CN CN201680022982.1A patent/CN107530344B/zh active Active
- 2016-04-20 BR BR112017020591A patent/BR112017020591B8/pt active IP Right Grant
- 2016-04-20 WO PCT/EP2016/058810 patent/WO2016170014A1/en active Application Filing
- 2016-04-20 HU HUE16719356A patent/HUE047162T2/hu unknown
- 2016-04-20 DK DK16719356.4T patent/DK3285772T3/da active
- 2016-04-20 PL PL16719356T patent/PL3285772T3/pl unknown
- 2016-04-20 CA CA2981631A patent/CA2981631C/en active Active
- 2016-04-20 US US15/565,866 patent/US10493074B2/en active Active
- 2016-04-20 MX MX2017013148A patent/MX2017013148A/es active IP Right Grant
- 2016-04-20 LT LTEP16719356.4T patent/LT3285772T/lt unknown
- 2016-04-20 SG SG11201707789YA patent/SG11201707789YA/en unknown
- 2016-04-20 ES ES16719356T patent/ES2763335T3/es active Active
- 2016-04-20 MY MYPI2017703917A patent/MY192972A/en unknown
- 2016-04-20 EP EP16719356.4A patent/EP3285772B1/en active Active
- 2016-04-20 KR KR1020177031275A patent/KR102627370B1/ko active IP Right Grant
-
2017
- 2017-09-28 IL IL254766A patent/IL254766B/en active IP Right Grant
- 2017-10-17 CO CONC2017/0010573A patent/CO2017010573A2/es unknown
- 2017-10-20 CL CL2017002669A patent/CL2017002669A1/es unknown
-
2019
- 2019-12-17 HR HRP20192273TT patent/HRP20192273T1/hr unknown
- 2019-12-23 CY CY20191101354T patent/CY1122572T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210529T1 (hr) | Inhibitori za mk2 i njihove uporabe | |
| CL2015000784A1 (es) | Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades. | |
| PT3262037T (pt) | Um novo derivado de quinolina para uso no tratamento e prevenção de infeções virais | |
| EA201690093A1 (ru) | Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний | |
| WO2014152029A3 (en) | Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors | |
| WO2013184876A8 (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
| PH12016501122A1 (en) | Delayed release compositions of linaclotide | |
| IL271352B (en) | A pharmaceutical preparation containing a derivative of glutarimide and its use in the treatment of eosinophilic diseases | |
| PL3261642T3 (pl) | Pochodne chinoliny do zastosowania w leczeniu lub zapobieganiu zakażeniom wirusowym | |
| EP3412292B8 (en) | Use of methoxatin, derivative and/or salt thereof in sjogren's syndrome and pharmaceutical composition | |
| EP3310375A4 (en) | USE OF LOW MOLECULAR WEIGHT HUMAN SERUM ALBUMIN FRACTIONS FOR TREATING DISEASES | |
| IL284125A (en) | History of quinoline for use in the treatment of inflammatory diseases | |
| CO2018013559A2 (es) | Análogo de trifluoroetil quinolina específico para usarse en el tratamiento del síndrome de fosfoinositida 3-cinasa delta activada (apds) | |
| WO2015106215A3 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| EP3488850A4 (en) | INNOVATIVE USE OF GZD824 AND PHARMACEUTICAL ACCEPTABLE SALTS THEREOF FOR THE TREATMENT OF DISEASES | |
| EP3600305A4 (en) | BERBERIN ALKALOID FORMULATIONS FOR THE PREVENTION AND / OR TREATMENT OF INFECTIOUS DISEASES | |
| HRP20192273T1 (hr) | Specifični trifluoroetil analozi kinolina za upotrebu u liječenju sjögrenovog sindroma | |
| HK1211288A1 (en) | Naphthyridinone derivatives and their use in the treatment,amelioration or prevention of a viral disease | |
| MA39912A (fr) | Dérivés de 2-aryl-4-hydroxy-1,3-thiazole comme antagonistes du trpm8, et leur utilisation dans le traitement de la neuralgie, de la douleur, de la bpco et de l'asthme. | |
| EP3533451A4 (en) | APPLICATION OF PAEENIFLORIN-6'-O-BENZENE SULFONATE IN MEDICINE FOR THE TREATMENT OF SJÖGREN SYNDROME | |
| IL274868A (en) | History of imidazopyridine and their use as medicine | |
| EP3065548A4 (en) | Fibrosis inhibiting compounds and methods of use thereof in the prevention or treatment of fibrosing diseases | |
| WO2020022975A3 (en) | New pharmaceutical compositions in the treatment of copd | |
| JP2018513862A5 (hr) |